Description:

CALGB 90601: Supplemental Adverse Event Form (Thromboembolic Events) NCT00942331 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=65940F04-CD97-54E2-E040-BB89AD435A8C

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=65940F04-CD97-54E2-E040-BB89AD435A8C

Keywords:
Versions (3) ▾
  1. 8/26/12
  2. 1/8/15
  3. 6/3/15
Uploaded on:

June 3, 2015

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

CALGB 90601: Supplemental Adverse Event Form (Thromboembolic Events) NCT00942331

INSTRUCTIONS: Complete and submit this form as required by the protocol. Information in the upper right box must be completed for this form to be accepted.

Header
Patient demographics
Assessment of medication